BACKGROUND: Proton pump inhibitors (PPIs) are widely prescribed to treat gastrointestinal diseases. However, concerns have been raised regarding their long-term use. Gastric acid suppression may decrease iron absorption, and it remains uncertain whether iron-deficiency anemia may result from chronic PPI therapy. AIMS: We aimed to explore the association between chronic PPI use and iron-deficiency anemia. METHODS: We conducted a retrospective cohort study of adult patients in an academic outpatient setting who received PPI therapy for at least 1 year between January 1, 2004 and January 1, 2006. We compared the change in hematologic indices among patients receiving PPI therapy for at least 1 year with matched controls. RESULTS: Of the 98 patients on chronic PPI therapy who met inclusion criteria, 35% had no documented indication for such therapy. At baseline, demographics and hematologic indices were similar between PPI-users and controls. Among patients on PPI therapy, all hematologic indices decreased from baseline, including hemoglobin (-0.19 g/dL, P=0.03), hematocrit (-0.63%, P=0.02), and mean corpuscular volume (-0.49 fL, P=0.05). PPI users had significant decreases in mean hemoglobin and hematocrit (P<0.01 for both) compared with matched controls. After adjustment for confounders, including rates of esophagogastroduodenoscopy, colonoscopy and remote cancer status, the odds ratio of decreasing hemoglobin by 1.0 g/dL while on chronic PPI therapy was 5.03 (95% CI, 1.71-14.78, P<0.01), while the odds ratio of decreasing hematocrit by 3% was 5.46 (95% CI, 1.67-17.85, P<0.01). CONCLUSIONS: Among adult patients receiving chronic PPI therapy, there is a significant decrease in hematologic indices from baseline.
BACKGROUND: Proton pump inhibitors (PPIs) are widely prescribed to treat gastrointestinal diseases. However, concerns have been raised regarding their long-term use. Gastric acid suppression may decrease iron absorption, and it remains uncertain whether iron-deficiency anemia may result from chronic PPI therapy. AIMS: We aimed to explore the association between chronic PPI use and iron-deficiency anemia. METHODS: We conducted a retrospective cohort study of adult patients in an academic outpatient setting who received PPI therapy for at least 1 year between January 1, 2004 and January 1, 2006. We compared the change in hematologic indices among patients receiving PPI therapy for at least 1 year with matched controls. RESULTS: Of the 98 patients on chronic PPI therapy who met inclusion criteria, 35% had no documented indication for such therapy. At baseline, demographics and hematologic indices were similar between PPI-users and controls. Among patients on PPI therapy, all hematologic indices decreased from baseline, including hemoglobin (-0.19 g/dL, P=0.03), hematocrit (-0.63%, P=0.02), and mean corpuscular volume (-0.49 fL, P=0.05). PPI users had significant decreases in mean hemoglobin and hematocrit (P<0.01 for both) compared with matched controls. After adjustment for confounders, including rates of esophagogastroduodenoscopy, colonoscopy and remote cancer status, the odds ratio of decreasing hemoglobin by 1.0 g/dL while on chronic PPI therapy was 5.03 (95% CI, 1.71-14.78, P<0.01), while the odds ratio of decreasing hematocrit by 3% was 5.46 (95% CI, 1.67-17.85, P<0.01). CONCLUSIONS: Among adult patients receiving chronic PPI therapy, there is a significant decrease in hematologic indices from baseline.
Authors: C A Stewart; B Termanini; V E Sutliff; J Serrano; F Yu; F Gibril; R T Jensen Journal: Aliment Pharmacol Ther Date: 1998-01 Impact factor: 8.171
Authors: P Michael Ho; Thomas M Maddox; Li Wang; Stephan D Fihn; Robert L Jesse; Eric D Peterson; John S Rumsfeld Journal: JAMA Date: 2009-03-04 Impact factor: 56.272
Authors: Emily Hailstone; Sheryl Falkos; Rosa Vidal; K Ashley Jones; Philippe R Gaillard; Shirley Fan; Allison M Chung Journal: J Pediatr Pharmacol Ther Date: 2021-05-19
Authors: Nicole D Ford; Laird J Ruth; Sarah Ngalombi; Abdelrahman Lubowa; Siti Halati; Martin Ahimbisibwe; Rhona Baingana; Ralph D Whitehead; Carine Mapango; Maria Elena Jefferds Journal: J Nutr Date: 2020-04-01 Impact factor: 4.798
Authors: Edward L Jones; Michael P Meara; Jennifer S Schwartz; Jeffrey W Hazey; Kyle A Perry Journal: Surg Endosc Date: 2015-06-27 Impact factor: 4.584